MedPath

Elite study.

Completed
Conditions
CF pos. pseudomonas infection
Registration Number
NL-OMON23558
Lead Sponsor
chiron corporated ltdgeneraal de witte laan 19a b52800 mechelen belgie
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

1. Male or female subject > 6 months;

Exclusion Criteria

1. History of aminoglycoside hypersensitivity
symptoms of acute pulmonary disease
invest. drugs within 30 days prior to enrollment;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary objective of this study is to estimate the duration of eradication of any strain of P aeruginosa infection during the 27 month study period following TNS treatment of early infection in cystic fibrosis patients.
Secondary Outcome Measures
NameTimeMethod
1. To estimate the proportion of subjects free form P aeruginosa at visit 5 with 300 mg twice daily for either 28 days or 56 days<br>to assess the safety of patients in the two treatment arms;<br /><br>2. To assess the proportion of patients requiring hospitalisation for pulmonary exacerbation.
© Copyright 2025. All Rights Reserved by MedPath